Comparison of two doses of imatinib for the treatment of unresectable or metastatic gastrointestinal stromal tumors (GIST): A meta-analyis based on 1,640 patients (pts)
M. M. Van Glabbeke(European Organisation for Research and Treatment of Cancer), Cathryn Rankin(Cleveland Clinic), Kouros Owzar(Duke University), John Crowley(AbbVie (United States)), John Simes(The University of Sydney)
Cited by 383
Related Papers
International uniform response criteria for multiple myeloma
|Leukemia|2006|2.6k
Adjuvant imatinib mesylate after resection of localised, primary gastrointestinal stromal tumour: a randomised, double-blind, placebo-controlled trial
|The Lancet|2009|1.4k
Lenalidomide after Stem-Cell Transplantation for Multiple Myeloma
|New England Journal of Medicine|2012|1.2k